FGF23抗体新药Crysvita

Crysvita, an Approved New Drug of FGF23 Antibody

摘要: FGF23是成纤维细胞生长因子家族(Fibroblast Growth Factor Superfamily, FGFs)的第23个成员，它可抑制肾小管磷酸盐再吸收和维生素D在肾脏的产生。Crysvita可结合XLH患者过量的FGF23，使其血磷水平正常化，从而改善骨矿化，以及儿童的软骨病和成人的骨折。本文就Crysvita作用机制、毒理学、临床研究、不良反应、注意事项等信息作以概述，希望能对临床用药提供帮助。

Abstract: Fibroblast growth factor 23 (FGF23), the 23th member of Fibroblast Growth Factor Superfamily (FGFs), which suppresses the renal tubular phosphate reabsorption and the renal production of vitamin D. Crysvita binds to and inhibits the biological activity of FGF23 in X-linked Hypophosphatemia (XLH) patients serum. Furthermore, it restores the renal phosphate reabsorption and increases the serum phosphorus levels, improving the bone mineralization and pediatric osteomalacia and adult ossium. Here we introduce the mechanism, toxicology, clinical study, adverse actions and precautions of Crysvita in order to provide some information for its clinic application.